MediciNova starts phase 1 trial of MN-246 for treatment of urinary incontinence

By Elaine Rigoli

Tampa, Fla., March 31 - MediciNova, Inc. has started its phase 1 clinical trial to determine the safety, tolerability and pharmacokinetics of MN-246, its novel oral treatment for urinary incontinence, in healthy human volunteers.

MN-246 is a selective Beta3-adrenergic receptor that represents a potential new approach to treating urinary incontinence, according to a news release.

Advantages over existing therapies include improvements in efficacy through increases in bladder volume with decreases in involuntary bladder contractions and the absence of anti-cholinergic side effects such as dry mouth, the company said.

Urinary incontinence is a symptom and not a disease in itself. A broad range of conditions and disorders can cause incontinence, including surgery, injuries, neurological diseases, infections and degenerative changes associated with aging. It can also occur as a result of pregnancy or childbirth.

"MN-246 may offer a unique approach to treating this common and distressing condition without the side effects (e.g., dry mouth, headache, blurred vision, constipation and abdominal pain) associated with currently available treatments," president and chief executive officer Yuichi Iwaki said in the release.

MediciNova said it acquired a license to MN-246 from Mitsubishi Pharma Corp. for global markets, with the exception of Japan and other selected Asian countries. The data acquired from Mitsubishi includes extensive preclinical test results.

MediciNova is a specialty pharmaceutical company based in San Diego.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.